Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
Andrea Favre-Bulle(MSD (Switzerland)), Arjun Bhadhuri(University of Basel)
Cited by 13
Related Papers
Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy
|Health and Quality of Life Outcomes|2020|61
Vitamin D Testing
|Unknown|2020|0